Lv41
420 积分 2024-05-15 加入
CD20 CAR-T Therapy Preemptively Treats Patients with Relapsed/Refractory DLBCL in Partial Remission after CD19 CAR-T
1个月前
已完结
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
6个月前
已完结
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma The FUMANBA-1 Nonrandomized Clinical Trial
11个月前
已完结
American Society of Hematology 2019 guidelines for immune thrombocytopenia
1年前
已关闭
A Comparative Study of Bayesian Optimal Interval (BOIN) Design With Interval 3 + 3 (i3 + 3) Design for Phase I Oncology Dose-Finding Trials
1年前
已完结
CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity
1年前
已完结
皖公网安备34019202002308
